Product Overview

Clofert 50 mg is a prescription tablet indicated for the treatment of female infertility caused by ovulatory dysfunction. Produced by Svizera Maneesh Pharma, each strip contains ten tablets, each delivering a precise 50 mg dose of the active agent. The medication is available in pack sizes of 30, 60, or 90 tablets, allowing clinicians to tailor treatment duration to individual patient needs. Packaging conforms to pharmaceutical standards, ensuring stability and accurate dosing throughout the treatment course.

What is Clofert 50 mg?

Clofert belongs to the class of selective estrogen receptor modulators (SERMs). Its principal component, clomiphene citrate, exerts a dual antagonistic‑agonist effect on estrogen receptors in the hypothalamus and peripheral tissues. By blocking estrogen‑mediated negative feedback, Clofert stimulates the hypothalamic release of gonadotropin‑releasing hormone (GnRH), which in turn prompts the anterior pituitary to secrete increased amounts of follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). This endocrine cascade promotes the growth of multiple ovarian follicles and prepares the endometrium for potential implantation.

Uses and Benefits

The primary therapeutic application of Clofert 50 mg is ovulation induction in women diagnosed with polycystic ovary syndrome (PCOS), hypothalamic amenorrhea, or other forms of anovulation. Clinical trials referenced by the National Institutes of Health (NIH) have demonstrated ovulation rates ranging from 70 % to 80 % and pregnancy rates of approximately 30 % per cycle when used according to established protocols. Compared with injectable gonadotropins, Clofert offers advantages of oral administration, lower cost, and ease of patient compliance. Additionally, its anti‑estrogenic activity on cervical mucus is minimal, preserving the natural fertile environment.

How It Works

Clomiphene citrate acts as a partial agonist at estrogen receptors located in the arcuate nucleus of the hypothalamus. This partial agonism reduces the inhibitory feedback of endogenous estrogen, leading to an up‑regulation of GnRH pulse frequency. The subsequent rise in GnRH stimulates the synthesis and release of FSH and LH from the pituitary gland. Elevated FSH supports the recruitment and maturation of multiple ovarian follicles, while the LH surge triggers ovulation approximately 36‑48 hours after the final oral dose. The drug’s long half‑life (approximately 6 days) permits once‑daily dosing, and its metabolite, norclomiphene, contributes to sustained pharmacodynamic activity.

Dosage Guidelines

Standard clinical practice initiates Clofert 50 mg once daily for five consecutive days, typically beginning on day 3 through day 5 of the menstrual cycle. This timing aligns with the early follicular phase, optimizing the window for follicular recruitment. Patients are advised to undergo baseline hormonal profiling, including serum FSH, LH, estradiol, and prolactin, as well as transvaginal ultrasound to assess ovarian reserve. If ovulation is confirmed, intercourse timed with the LH surge or intrauterine insemination can be scheduled. In subsequent cycles, the same regimen may be repeated after an interval of at least 30 days, provided pregnancy has not occurred. Dosage escalation to 100 mg is reserved for documented non‑responders and must be supervised by a qualified physician.

Side Effects

Adverse events associated with Clofert are generally mild to moderate and include hot flashes, abdominal discomfort, breast tenderness, and occasional nausea. Less common but clinically significant reactions comprise visual disturbances, headache, and ovarian hyperstimulation syndrome (OHSS), characterized by abdominal distension, rapid weight gain, and shortness of breath. The U.S. Food and Drug Administration (FDA) emphasizes immediate medical evaluation if severe pelvic pain, dyspnea, or signs of thromboembolic events develop. Long‑term administration beyond six ovulation cycles is discouraged without specialist oversight due to potential risks of ovarian tumor formation and cumulative estrogenic exposure.

Warnings and Precautions

Clofert is contraindicated in individuals with hepatic impairment, ovarian cysts unrelated to PCOS, and known hypersensitivity to clomiphene or any excipients in the formulation. Prior to initiation, a comprehensive medical history should exclude pituitary adenomas, thyroid disorders, and adrenal insufficiency, all of which may affect treatment response. Concomitant use of certain antidepressants, such as SSRIs, or hormonal therapies may alter pharmacokinetic dynamics; therefore, clinicians should review all current medications. Pregnant women must avoid exposure, and healthcare providers should counsel patients regarding the increased likelihood of multiple gestation, which occurs in roughly 5‑10 % of pregnancies following clomiphene induction. Proper storage at room temperature, protected from moisture and light, ensures tablet integrity throughout the treatment period.

Additional Considerations

Patients initiating Clofert therapy should undergo baseline pelvic ultrasound to document ovarian morphology and to rule out pre‑existing cysts or neoplasms. Throughout each treatment cycle, serial ultrasound examinations are recommended to track follicular growth and to detect early signs of ovarian hyperstimulation. Serum estradiol levels can be measured on the day of human chorionic gonadotropin (hCG) administration to assess response. If three consecutive cycles fail to induce ovulation, a thorough reevaluation — including assessment of partner sperm parameters, tubal patency, and male factor infertility — should be undertaken. Lifestyle modifications such as weight management, regular exercise, and cessation of smoking have been shown to improve ovulatory rates and should be encouraged as adjunctive measures. Finally, clinicians must document all medication exposures and adverse events in the patient’s medical record to facilitate pharmacovigilance and future treatment planning.

Drug Interactions and Contraindications

Concomitant administration of Clofert with agents that affect hepatic enzymes, such as certain anticonvulsants (e.g., carbamazepine) or herbal supplements (e.g., St. John’s wort), may alter clomiphene metabolism and diminish therapeutic efficacy. Patients should be instructed to disclose all prescription medications, over‑the‑counter drugs, and dietary supplements to their healthcare provider before initiating therapy. Additionally, clomiphene is contraindicated in individuals with known hypersensitivity to the drug, active liver disease, or ovarian cysts unrelated to polycystic ovary syndrome. Caution is advised when prescribing Clofert alongside hormonal contraceptives, as their combined use may interfere with ovulation induction goals.

Frequently Asked Questions

1. How long does it take to see ovulation after starting Clofert? Ovulation typically occurs 6‑12 days after the final dose, though individual variation exists; ultrasound monitoring is advised to confirm follicular development and timing of the LH surge.
2. Can Clofert be used by women with polycystic ovary syndrome? Yes, the FDA has approved clomiphene for ovulation induction in PCOS, but clinicians should evaluate insulin resistance, body mass index, and lifestyle factors to optimize outcomes and reduce the need for higher dosages.
3. Is Clofert safe for extended use? Current guidelines recommend limiting treatment to a maximum of six ovulatory cycles. Prolonged use beyond this period is associated with increased risk of ovarian hyperstimulation and potential tumor development, and should only be considered under the supervision of a fertility specialist.
4. What should I do if I miss a dose? If a scheduled dose is missed, the tablet should be skipped and the regular dosing schedule resumed; taking a double dose is not recommended and may increase the likelihood of adverse effects.
5. Are there dietary restrictions while taking Clofert? No specific dietary exclusions are required; however, maintaining a balanced nutrition plan, adequate hydration, and a healthy body weight can enhance ovulatory response and overall treatment success.

For comprehensive prescribing information, consult the FDA prescribing label, the MedlinePlus drug entry, and peer‑reviewed studies indexed in PubMed. Additional scientific context is available through the NIH Bookshelf and the Royal Society of Chemistry database.

Related Products

• ZyhCG 10000 (HCG 10000iu)
• ZyhCG 5000 (HCG 5000iu)
• ZyhCG 2000 (HCG 2000iu)
• Sifasi Aqua 5000 (HCG (Human Chorionic Gonadotropin))
• Clomiphene 50 mg (Generic)
• Clomiphene 100 mg (Generic)
• Clomiphene 25 mg (Generic)
• Progesterone Vaginal Gel 1.125 g (Generic)
• Fertomid 25 mg (Clomiphene)
• Clofert 25 mg (Clomiphene)
• Clofert (Clomiphene)
• Clofert 100 mg (Clomiphene)